The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape

Key takeaways

• Novartis committed up to $100 million upfront to Unnatural Products in February 2026 for macrocyclic peptide cardiovascular programmes, with potential milestones reaching $1.7 billion.
• Syneron Bio closed a $150 million Series B in April 2026 to scale its AI-driven Synova macrocyclic platform, backed by investors including AstraZeneca, Temasek, and the Abu Dhabi Investment Authority.
• AstraZeneca's $3.4 billion biobucks collaboration with Syneron, signed in March 2025, remains one of the largest platform-level macrocycle deals on record.
• The scientific rationale centres on macrocycles' ability to engage protein targets that neither small molecules nor conventional peptides can drug effectively — a structural advantage that is increasingly supported by published chemistry.
• For research labs, macrocyclic scaffolds present distinct procurement and handling considerations relative to linear peptides.

What macrocyclic peptides are — and why they are attracting capital

Macrocyclic peptides are short amino acid chains in which the N- and C-termini, or side chains, are covalently linked to form a ring structure. Macrocyclic peptides have been described as a "goldilocks" drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. The structural constraint conferred by cyclisation improves proteolytic stability, reduces conformational entropy, and — depending on the specific scaffold — can substantially improve membrane permeability and oral bioavailability relative to their linear counterparts.

Peptides as a therapeutic modality attract attention due to their synthetic accessibility and high degree of specific binding, as well as their ability to target protein surfaces traditionally considered undruggable. At the same time, other pharmacological properties of a generic peptide, such as metabolic stability and cell permeability, are quite poor, which limits the success of de novo discovered biologically active peptides as drug candidates. Macrocyclisation addresses precisely these liabilities by locking the molecule into a defined three-dimensional shape, reducing the entropic penalty on binding and shielding backbone amide bonds from proteases.

Macrocyclic peptides, with their intermediate size, combine the properties of both small molecules and biologics. With their larger size and unique ring shape, they can tightly bind ample surface area to disrupt protein-protein interactions compared to traditional, linear-shaped peptide therapies.

The 2026 deal cluster: three transactions in three months

Novartis and Unnatural Products — February 2026

Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced a research collaboration and licensing agreement with Novartis on an undisclosed programme. The collaboration brings together UNP's AI-enhanced macrocycle platform and Novartis' global development and commercialization capabilities to generate next-generation therapeutics with potential applications in the cardiovascular disease area.

The $100 million that Novartis is committing to UNP is a combination of upfront and pre-IND milestone payments. Achieving development, regulatory, and commercial milestones could bring the startup up to $1.7 billion more. UNP would also receive royalties from sales of a commercialised product.

Novartis will assume responsibility for IND-enabling studies and all subsequent clinical development, manufacturing, and global commercialisation of products emerging from the collaboration.

This arrangement was not Unnatural Products' first institutional validation. The company has established collaborations with leading pharmaceutical and biotechnology companies including Novartis, Merck, BridgeBio and argenx to apply its macrocyclic platform across multiple therapeutic areas. Weeks after the Novartis announcement, Unnatural Products raised $45 million in a Series B financing round, having previously announced a licensing agreement with Novartis to develop macrocyclic peptide therapeutics for historically undruggable cardiovascular targets, including up to $100 million upfront and up to $1.7 billion in total potential milestones.

Syneron Bio Series B — April 2026

Beijing-based Syneron Bio closed a USD 150 million Series B financing round to advance its macrocyclic peptide drug discovery platform and accelerate its pipeline toward clinical development across oncology, autoimmune, metabolic, and rare diseases.

The round was co-led by an unnamed international life sciences fund, Decheng Capital, and CDH VGC. Additional participants included a wholly owned subsidiary of the Abu Dhabi Investment Authority, True Light Capital — an independent subsidiary of Temasek — Qiming Venture Partners, and BioTrack Capital. Existing shareholders AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital also participated.

The company utilises its proprietary Synova platform — an intelligent, high-throughput discovery platform — to design, screen, and optimise peptide drugs to address significant unmet medical needs. The company is building a pipeline focused on oncology and chronic diseases, including autoimmune and metabolic disorders. Synova combines AI, data science, and high-throughput screening to improve the efficiency and success rate of identifying macrocyclic peptides that combine the specificity of biologics with the drug-like properties of small molecules.

The Series B follows a March 2025 partnership with AstraZeneca. The platform has drawn external validation through a research collaboration and licensing agreement with AstraZeneca, structured around access to Synova for the discovery of macrocyclic peptide candidates in chronic diseases. That deal carries potential milestone payments of up to USD 3.4 billion, with tiered royalties on any commercialised products.

A disclosed preclinical candidate, SYNB021225, illustrates the scientific ambition behind the platform. The company's two disclosed preclinical candidates both sit in oncology. SYNB021225 is designed as an orally bioavailable pan-KRAS inhibitor, targeting multiple KRAS mutant variants — a broader approach than the allele-specific inhibitors currently approved.

Why big pharma is paying platform premiums

Several forces are converging to make macrocyclic peptide platforms attractive at scale.

Undruggable target access. Many of the most commercially attractive biological targets — including protein-protein interaction interfaces and intracellular signalling nodes such as KRAS — have historically resisted small-molecule drug design. Merck scientists began investigating a way to create a new kind of medicine that would combine the potency and precise targeting of an antibody with the stability and ease of administration of a small molecule or pill. "Macrocyclic peptides allow us to cast a wider net on the protein interactions we want to drug, providing a vast and untapped opportunity to access a wider range of targets and potentially new ways to treat different diseases," according to Merck's director of chemistry.

Oral delivery potential. Conventional injectable peptides face significant patient-adherence and cold-chain costs. Unnatural Products' CEO has stated that the platform "unlocks the precision of biologics with the delivery advantages of small molecules, enabling us to target complex intracellular pathways that have historically been out of reach," and that it "can also provide oral solutions to targets only currently addressable with costly injectables."

AI-accelerated discovery. Both Syneron Bio's Synova platform and Unnatural Products' parallel-experimentation-plus-machine-learning engine represent a generation of discovery tools that compress the hit-to-lead cycle. Advances in automated synthesis, high-throughput screening, and AI-enabled structure prediction are transforming how peptides are developed, evaluated, and scaled. As these technologies continue to mature, the timelines from lead identification to clinical validation are getting shorter.

Market scale. The global cyclic peptide market is experiencing steady growth, driven by their unique structural advantages compared to linear peptides. The market is projected to reach nearly US $3.6 billion in 2026 with a CAGR of 6.5–6.7%, leading to about US $5.3 billion by 2032. Biopharmaceutical applications dominate, particularly in oncology, autoimmune disorders, and infectious diseases, supported by advancements in solid-phase synthesis, display screening platforms, and computational design.

Implications for research-procurement professionals

The capital concentration in macrocyclic peptide platforms has several near-term implications for UK research laboratories.

Reagent and reference standard availability. As macrocyclic scaffolds move from discovery into IND-enabling studies, demand for high-purity reference compounds — including pan-KRAS macrocycles and macrocyclic IL-1β inhibitors — is likely to increase. Procurement teams should anticipate tighter availability windows and longer lead times for novel macrocycles compared with well-established linear peptides that have mature synthetic routes.

Characterisation complexity. Macrocyclic peptides present distinct analytical challenges. The ring constraint can complicate NMR interpretation, and mass spectrometric confirmation of cyclisation — rather than a simple linear sequence — requires careful attention to fragmentation patterns. Procurement teams specifying third-party testing should ensure Certificates of Analysis explicitly confirm cyclisation status, not merely molecular weight.

Cold chain and storage. The stability profile of macrocyclic peptides varies by scaffold. The conformational rigidity that confers protease resistance in vivo does not necessarily translate to improved lyophilised-powder stability under ambient temperature; many macrocycles retain hygroscopic and light-sensitive properties similar to their linear counterparts. Standard reconstitution protocols using bacteriostatic water remain applicable, but storage at −20 °C is advisable until compound-specific stability data is available.

Supplier verification. The rise of peptide therapeutics is creating new demands across the development pipeline. As peptides continue to occupy the space between small molecules and biologics, new standards are being established for purity characterisation, formulation stability, and in vivo efficacy profiling. The same supplier-quality considerations that apply to linear research peptides — third-party HPLC purity data, mass spectrometry confirmation, and traceable batch documentation — are equally relevant for macrocyclic compounds, where adulteration may be harder to detect by visual inspection alone.

What to watch

The Syneron Bio Series B press release indicates that IND-enabling studies are planned across multiple programmes, with filings targeted at both the NMPA in China and the FDA. The Unnatural Products pipeline spans cardiovascular, oncology, rare disease, and immunology indications. Bicycle Therapeutics, the Cambridge-founded macrocyclic peptide company now in clinical trials with its bicyclic BT8009 bladder cancer conjugate, provides the closest indication of how late-stage development of these molecules proceeds in practice.

The broader macrocycle investment cycle also reflects a wider biopharma M&A dynamic: biopharma companies pulled off seven transactions in the last two weeks of March alone worth a combined $29 billion, indicating that 2026 will be a prime year for M&A. Platform-level peptide deals, including macrocyclic targets, are a recognised component of that trend, as acquirers seek to secure access to modalities that offer both target novelty and IP defensibility.

For UK research laboratories, the practical near-term question is less about clinical timelines and more about ensuring that macrocyclic reference compounds entering procurement workflows are sourced from suppliers with the analytical rigour to confirm ring integrity — a characterisation step that is easy to omit and difficult to retrospectively correct once an experiment is underway.